Showing 1,101 - 1,120 results of 116,996 for search '(( a non decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.74s Refine Results
  1. 1101
  2. 1102
  3. 1103

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  4. 1104
  5. 1105

    Decrease in the frequency of FGF-2/EGF addition increases cell death in aOBSCs. by Vanesa Nieto-Estévez (107326)

    Published 2013
    “…Graphs show the percentage of cells in each group (<b>D</b>, E13.5 OBSCs; <b>H</b>, aOBSCs). The results represent the mean ± SEM from 3–5 passages from 2 different cell cultures per condition. …”
  6. 1106

    Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

    Published 2013
    “…The relative expression (2<sup>-ΔΔCt</sup> mean ± SEM) of hepatic CYP3A4 mRNA was significantly higher in cirrhotic livers (21.76 ± 2.65 vs. 5.91 ± 1.29, P=2.04E-07) but their levels did not significantly correlate with hepatic CYP3A activity (r=-0.43, P=0.08).…”
  7. 1107
  8. 1108
  9. 1109
  10. 1110
  11. 1111
  12. 1112
  13. 1113
  14. 1114
  15. 1115
  16. 1116

    Deterioration of the anammox process at decreasing temperatures and long SRTs by Maaike Hoekstra (3915545)

    Published 2017
    “…The long SRT leads to an increase of non-active and non-anammox cells in the reactor, thereby decreasing the biomass-specific activity.…”
  17. 1117
  18. 1118

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  19. 1119
  20. 1120